Previous close | 0.5500 |
Open | 0.5500 |
Bid | 0.0000 |
Ask | 0.8500 |
Strike | 22.50 |
Expiry date | 2024-05-17 |
Day's range | 0.5500 - 0.5500 |
Contract range | N/A |
Volume | |
Open interest | 36 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Overview of Financial Performance and Future Prospects
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights. “I am excited about